Figure 7.

Platform trial. Patients are screened for known biomarkers A and B. Biomarker A + subjects are randomized into drug 1 and 2 versus standard of care. When drug 1 meets criteria for success, it replaces previous standard of care as control. If new drug 5 becomes available, the patients are randomized to this group. Similarly, if drug 3 shows no benefit, the stratum is stopped and biomarker B+ subjects are assigned into biomarker negative stratum. If at some point a new biomarker C and drug 6 becomes available, a new stratum is opened with subsequent screening of patients and assignment to Group A and C